ArticleScientific reports2026
Comparison of new and recurring post-acute infection syndrome - results from a German population-based cohort.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New respiratory infections after or while experiencing post-acute infectious syndromes (PAIS) can lead to resurgence of symptoms. Data comparing symptoms, related impairment, and duration of first and recurring PAIS episodes are lacking. This cross-sectional study was conducted in September/October 2025 within a large population-based digital cohort in Germany (DigiHero, registered under DRKS00025600). We included data from 2,801 participants retrospectively reporting a respiratory infection between September 2024 and August 2025 with subsequent long-lasting symptoms ≥ 12 weeks after infection. We compared self-reported first and recurring PAIS episodes. Of detected PAIS cases, 57% (n = 1,609) were the first episode and 43% (n = 1,192) already experienced a PAIS episode in the past. While symptom patterns were broadly similar, those reporting recurring PAIS without full recovery from a previous episode (n = 308) displayed a higher number and longer duration of long-lasting symptoms and a higher level of impairment due to their symptoms compared to those with first PAIS episodes or recurring cases that were fully recovered at the time of the new infection (n = 303). Among participants with recurring PAIS who compared their most recent with their first episode, 43% reported similar impairment, while 32% reported greater and 26% lower impairment. While after the COVID-19 pandemic PAIS is still occurring, a substantial proportion of all PAIS cases in 2024/25 in the DigiHero cohort resulted from those with recurring PAIS. Symptom profiles were in general similar for first and recurring PAIS episodes. However, recurring cases exhibited greater impairment and longer symptom duration, when they did not fully recover from a preceding PAIS episode before the new infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.